Raptor Pharmaceuticals’ Experimental Therapy in Phase 2 / 3 Trial for Leigh Syndrome
Kearns-Sayre syndrome, Leigh syndrome, Mitochondrial DNA depletion syndrome, Progressive external ophthalmoplegia
Raptor Pharmaceuticals Inc. is looking to bring relief to a wide variety of young patients with inherited mitochondrial disease through its therapeutic called RP103 (cysteamine bitartrate delayed-release capsules). A Phase ... Read more